Stay updated on Nivolumab, Cabiralizumab, SBRT in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab, Cabiralizumab, SBRT in Pancreatic Cancer Clinical Trial page.

Latest updates to the Nivolumab, Cabiralizumab, SBRT in Pancreatic Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now shows revision v3.6.6 in place of v3.6.5, indicating a maintenance update rather than changes to the trial information.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe page's revision label changed from v3.6.4 to v3.6.5, representing an updated version of the study page.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page’s revision tag was updated from v3.6.3 to v3.6.4, signaling a new version of the page or its backend patch. This change reflects an internal update rather than a substantive modification to the displayed information.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page revision tag was updated from v3.6.2 to v3.6.3, indicating a small maintenance update to the page metadata.SummaryDifference0.1%

- Check79 days agoChange DetectedRevision: v3.6.2 was added, replacing the previous v3.6.0. This reflects a minor administrative update to the page’s revision history.SummaryDifference0.1%

- Check94 days agoChange DetectedThe page now indicates recruitment has ended ('No longer looking for participants'), adds user-help sections ('How to Read a Study Record', 'Common Questions', 'How to Join a Study') and a new 'Intervention/Treatment' section, replaces the old 'Intervention / Treatment' heading, and updates the Revision tag from v3.5.5 to v3.6.0.SummaryDifference0.6%

Stay in the know with updates to Nivolumab, Cabiralizumab, SBRT in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab, Cabiralizumab, SBRT in Pancreatic Cancer Clinical Trial page.